A detailed history of Geode Capital Management, LLC transactions in Immunome Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,207,455 shares of IMNM stock, worth $12.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,207,455
Previous 1,062,898 13.6%
Holding current value
$12.6 Million
Previous $12.9 Million 37.25%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$11.7 - $16.51 $1.69 Million - $2.39 Million
144,557 Added 13.6%
1,207,455 $17.7 Million
Q2 2024

Aug 09, 2024

BUY
$11.54 - $22.11 $7.28 Million - $13.9 Million
630,419 Added 145.77%
1,062,898 $12.9 Million
Q1 2024

May 13, 2024

BUY
$11.01 - $27.34 $1.23 Million - $3.05 Million
111,641 Added 34.8%
432,479 $10.7 Million
Q4 2023

Feb 13, 2024

BUY
$7.3 - $10.73 $1.72 Million - $2.53 Million
236,130 Added 278.76%
320,838 $3.43 Million
Q3 2023

Nov 13, 2023

BUY
$6.17 - $9.16 $21,564 - $32,014
3,495 Added 4.3%
84,708 $707,000
Q4 2022

Feb 13, 2023

SELL
$2.21 - $5.0 $426 - $965
-193 Reduced 0.24%
81,213 $178,000
Q1 2022

May 13, 2022

BUY
$3.88 - $13.99 $5,579 - $20,117
1,438 Added 1.8%
81,406 $462,000
Q4 2021

Feb 11, 2022

BUY
$12.96 - $23.44 $327,875 - $593,008
25,299 Added 46.28%
79,968 $1.04 Million
Q3 2021

Nov 12, 2021

BUY
$12.5 - $27.76 $189,250 - $420,286
15,140 Added 38.3%
54,669 $1.33 Million
Q2 2021

Aug 13, 2021

SELL
$16.33 - $32.33 $160,066 - $316,898
-9,802 Reduced 19.87%
39,529 $683,000
Q1 2021

May 12, 2021

BUY
$9.56 - $43.24 $326,483 - $1.48 Million
34,151 Added 224.97%
49,331 $1.67 Million
Q4 2020

Feb 12, 2021

BUY
$9.46 - $14.16 $143,602 - $214,948
15,180 New
15,180 $146,000

Others Institutions Holding IMNM

About Immunome Inc.


  • Ticker IMNM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,127,400
  • Market Cap $127M
  • Description
  • Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...
More about IMNM
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.